This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorUniversity of Central Florida

About this trial

Oral Melatonin is a commercially available product available alone and as a constituent in a number of supplements. Previous research suggests that short-term supplementation with oral melatonin may amplify the recovery response to damaging resistance exercise via modulation of subsequent immune and inflammatory responses. However the effects of oral melatonin on neutrophil and monocyte invasion/migration, a critical step in the resolution of skeletal muscle tissue homeostasis, has not been examined. An oral melatonin supplement (5mg) will be provided three times daily beginning 24-hours before and ending 48-hours after an acute bout of damaging resistance exercise (total 15mg/day for 3 days).

Goals:

1. To investigate the effect of melatonin on systemic and cellular responses following an acute bout of damaging resistance exercise. 2. To investigate the effect of melatonin on measures of functional performance before and during recovery from an acute bout of damaging resistance exercise.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Male or female between the ages of 18-40 years old.

Healthy and ready for physical activity as determined by the Physical Activity Readiness Questionnaire (PAR-Q+) and Medical History Questionnaire (MHQ).

Active resistance training for a minimum of 6 months as defined by 3 resistance training sessions (muscle strengthening activities such as free weights, weight machines, or calisthenics, etc.) per week with at least one lower body session as determined by the training history questionnaire.

Premenopausal, with an identifiable onset of menses (early follicular phase) as determined by the menstrual status questionnaire (female participants only)..

Disqualifiers

Individual does not agree to participate in this study.

Individual does not meet inclusion criteria to participate in the study protocols as determined via the PAR-Q+, medical history questionnaire, training history questionnaire, and/or the caffeine consumption questionnaire.

Currently taking melatonin

Regularly taking any type of prescription or over-the-counter medication which might affect the assessments, or having any chronic illnesses, which require medical care.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Melatonin

    Dietary supplement

    Gummy - 7.5 kilocalories (kCal), 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin.

  • Placebo

    Dietary supplement

    Gummy - 12.5 kilocalories (kCal), 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium.

Treatment groups

24 Participants
are divided into 2 treatment groups
Group A: MelatoninExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Subjective Sleep Duration

Participants provide information about sleep duration the previous night using the Hooper Questionnaire administered via pen and paper. Response is rated on a seven-point Likert scale with the following responses: * 10+ * 9-10 * 8-9 * 8 * 7-8 * 5-7 * 5 or less

Time frame
Pre (0), Immediately-post (IP), 4-hours Post (4H), 24-hours post (24H), 48-hours post (48H)
2

Subjective Sleep Quality

Participants provide information about their sleep quality the previous night using the Hooper Questionnaire administered via pen and paper. Response is rated on a seven-point Likert scale with the following responses: * Outstanding * Very good * Good * Better than normal * Worse than normal * Disrupted * Horrible - No Sleep

Time frame
Pre (0), Immediately-post (IP), 4-hours Post (4H), 24-hours post (24H), 48-hours post (48H)
3

Subjective Fatigue

Participants provide information about their current level of fatigue using the Hooper Questionnaire administered via pen and paper. Response is rated on a seven-point Likert scale with the following responses: * No Fatigue * Minimal Fatigue * Better than normal * Normal * Worse than normal * Very Fatigued * Exhausted - Major fatigue

Time frame
Pre (0), Immediately-post (IP), 4-hours Post (4H), 24-hours post (24H), 48-hours post (48H)
4

Subjective Muscle Soreness

Participants provide information about their current level of muscle soreness using the Hooper Questionnaire administered via pen and paper. Response is rated on a seven-point Likert scale with the following responses: * No Soreness * Very little soreness * Better than normal * Normal * Worse than normal * Very sore/tight * Extremely sore/tight

Time frame
Pre (0), Immediately-post (IP), 4-hours Post (4H), 24-hours post (24H), 48-hours post (48H)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: